12 Results for "

DOPE-PEG2000-CREKA

" in MedChemExpress (MCE) Product Catalog:
Products (12)

12 Results for "DOPE-PEG2000-CREKA" in MCE Product Catalog:

Cat. No.: HY-187490A
Synonyms: DOPE-PEG2000-Mal-Cys-CREKA
DOPE-PEG2000-CREKA (DOPE-PEG2000-Mal-Cys-CREKA) is an amphiphilic lipid-PEG-peptide conjugate consisting of DOPE (1,2-dioleoyl-sn-glycero-3-phosphoethanolamine), PEG2000, and the CREKA peptide (Cys-Arg-Glu-Lys-Ala), a tumor-homing peptide identified by in vivo phage display. DOPE-PEG2000-CREKA is used for tumor stroma-targeted drug delivery.
loading...
    loading...
Cat. No.: HY-P10709
CAS No.: 847058-45-1
Target:  

Collagen

Research Areas:  

Cardiovascular Disease Cancer

CREKA peptide is a selective non-covalent binding agent targeting fibrin, type IV collagen, and fibronectin, often used as a targeting ligand to modify delivery carriers. CREKA peptide specifically recognizes fibrin, fibronectin, and type IV collagen that are excessively deposited in the tumor microenvironment or fibrotic tissue, mediating the targeted accumulation of the carrier at the lesion site and promoting drug internalization into target cells (such as cancer cells and activated hepatic stellate cells). CREKA peptide can enhance targeted delivery efficiency, increase drug concentration at the lesion site, and reduce systemic side effects .
loading...
    loading...
Cat. No.: HY-P10392AF
Target:  

Wnt β-catenin

Research Areas:  

Cancer

fStAx-35R TFA is the hydrocarbon-stapled peptide. fStAx-35R TFA inhibits Wnt/β-catenin signaling pathway by disrupting the β-catenin-TCF interaction. fStAx-35R TFA can be used in cancer research .
loading...
    loading...
Cat. No.: HY-P10709A
Research Areas:  

Cardiovascular Disease Cancer

CREKA peptide acetate is a short peptide sequence, belonging to self-assembling peptides (SAPs), which can self-assemble into functional nanostructures, typically nanofibers, under physiological conditions. CREKA peptide acetate can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity .
loading...
    loading...
Cat. No.: HY-P10896
CAS No.: 1446005-10-2
Target:  

Bombesin Receptor

Research Areas:  

Cancer

NOTA-P2-RM26 is an antagonist of Bombesin (HY-P0195) analogs, and the gastrin-releasing peptide receptor (GRPR/BB2) is a molecular target for prostate cancer visualization. NOTA-P2-RM26 is labeled with 111In and 68Ga for prostate cancer imaging studies using PET and SPECT/CT .
loading...
    loading...
Cat. No.: HY-169232
Target:  

PROTACs PD-1/PD-L1

Research Areas:  

Cancer

PCC16 chloride is a dual PROTAC degrader targeting DHHC3 and PD-L1, with a DC50 of 0.103 μM for PD-L1 degradation. PCC16 chloride induces DHHC3 degradation via the ubiquitin-proteasome pathway by recruiting the CRBN E3 ubiquitin ligase (E3 ubiquitin ligase). By targeting DHHC3-which is essential for PD-L1 palmitoylation and membrane stability-PCC16 chloride reduces PD-L1 levels, decreases PD-L1 membrane retention time, and impairs its immunosuppressive function. PCC16 chloride enhances anti-tumor immunity by disrupting PD-L1-mediated immunosuppression. PCC16 chloride can be used in the research of immune checkpoint blockade-resistant cancers .
loading...
    loading...
Cat. No.: HY-P11054
Target:  

Peptides

Research Areas:  

Cancer

CREKA-YpFFK(Nph) is a gold nanoparticle surface ligand composed of CREKA and YPFFK (Nph), responsible for tumor targeting and alkaline phosphatase-responsive bond cleavage, respectively. CREKA-YpFFK(Nph) can be used for tumor targeting research .
loading...
    loading...
Cat. No.: HY-P11625
Target:  

RXFP Receptor

Research Areas:  

Cardiovascular Disease

R9-13 is a fatty acid-conjugated relaxin and an agonist of LGR7 (RXFP1). R9-13 induces sustained pubic symphysis elongation in estrogen-pretreated mice. R9-13 exhibits long-acting pharmacokinetic profiles in rodents, with in vivo activity lasting up to one week after administration. R9-13 can be used in studies related to acute heart failure .
loading...
    loading...
Cat. No.: HY-P11830
Target:  

Amylin Receptor

Research Areas:  

Metabolic Disease

UDA-6 is a potent calcitonin and amylin receptor agonist (DACRA). UDA-6 induces weight loss, improves metabolic and hepatic parameters, and stabilizes active receptor states in obesity rats. UDA-6 can be used for the research of obesity .
loading...
    loading...
Cat. No.: HY-P11596
CAS No.: 3107808-75-0
Target:  

Integrin

Research Areas:  

Cancer

NOTA-Asp2-αvβ6L is an integrin αvβ6 binder with selective accumulation in αvβ6-positive pancreatic cancer cells and tumors. NOTA-Asp2-αvβ6L can be used as a PET/CT tracer for imaging pancreatic ductal adenocarcinoma (PDAC) .
loading...
    loading...
Cat. No.: HY-P11846
Target:  

ADAMTS

Research Areas:  

Cardiovascular Disease

ADA2 is an ADAMTS4-binding peptide and imaging agent with a human ADAMTS4 Ka of 5.3 nM and reduced renal uptake compared to related tracers. ADA2 accumulates in dilated aortic regions in aortic aneurysm mouse models. ADA2 exhibits an in vivo safety profile. ADA2 can be used for the research of aortic aneurysm .
loading...
    loading...
Cat. No.: HY-P3252AS
Pegcetacoplan- 13C3, 15N TFA is the 13C- and 15N-labeled Pegcetacoplan TFA. Pegcetacoplan is a pegylated complement C3/C3b inhibitor. Pegcetacoplan acts by specifically binding to and inhibiting C3 and C3b, thereby suppressing the complement cascade at its proximal stage. Pegcetacoplan is not a known inhibitor or inducer of CYP450 isoenzymes. Pegcetacoplan can be used for the research of complement-mediated diseases, including paroxysmal nocturnal hemoglobinuria (PNH) and age-related macular degeneration (AMD).
loading...
    loading...
  • 1